When you look at the FDA clinical trials site there are still two trials that the site says are still recruiting patients:
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis (NCT04548583), and Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (NCT04543994).
We are supposed to have the final results of these two trials sometime in October 2023. Has anyone have any news about the final results of these trials and why they are still recruiting patients? They have already published the interim results, which was promising.
Colitis Indication
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |